Floatz logo

Bezuclastinib

Gastrointestinal Stromal Tumor

Cogent Biosciences, Inc.Small moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Gastrointestinal Stromal Tumor cohort.

Asset / SponsorPhaseRating
Midazolam
Blueprint Medicines Corporation
Phase 4BBB
Regorafenib
Institut Bergonié
Phase 4BBB
Esomeprazole
Erasmus Medical Center
Phase 4BB
Caffeine
Markus Joerger
Phase 4BB
Imatinib
M.D. Anderson Cancer Center
Phase 2BB

View all 49 →

Same molecule, other indications

Bezuclastinib is also rated in:

metastatic malignant neoplasmActive
CCC
Indicative · Phase 3
54 / 100
View asset →
systemic mastocytosisActive
CCC
Indicative · Phase 2
53 / 100
View asset →
systemic mastocytosis with an associated clonal hematologic non-mast cell lineage diseaseActive
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →